Great Hill Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Great Hill Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,134	Closed	-$2.52M	–	58
2025 Q3	$2.52M	Buy	+25,134	New	+$2.26M	0.39%	34

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Great Hill Capital's XBI Position: Q4 2025 in Review

Great Hill Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 25,134 shares — an estimated $2.52M sold.

Great Hill Capital first reported a position in XBI in Q3 2025 and held it in 1 quarter. The position peaked at $2.52M in Q3 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

Great Hill Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
Great Hill Capital sold 25,134 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $2.52M.
Great Hill Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2025 and held it in 1 quarter.
Great Hill Capital's State Street SPDR S&P Biotech ETF position peaked at $2.52M in Q3 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Great Hill Capital's 13F filing for Q4 2025, filed 26 Jan 2026.